Carisma Therapeutics (CARM) 10-Q 2017 Q3 Quarterly report

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. §1350

In connection with the Quarterly Report on Form 10-Q of Eleven Biotherapeutics, Inc. (the “Company”) for the fiscal quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, that, to the best of their knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/   Stephen A. Hurly        

Stephen A. Hurly

President and Chief Executive Officer

(Principal Executive Officer)

Dated: November 17, 2017

/s/ Richard F. Fitzgerald      

Richard F. Fitzgerald

Interim Chief Financial Officer

(Principal Financial Officer)

Dated: November 17, 2017